Assessment of the Particularities of Thrombophilia in the Management of Pregnant Women in the Western Part of Romania

Medicina (Kaunas). 2023 Apr 28;59(5):851. doi: 10.3390/medicina59050851.

Abstract

Background and objectives: Thrombophilia in pregnant women is a condition whose incidence is constantly increasing worldwide, and, under these conditions, the development of preventive procedures is becoming essential. In this study, we aimed to evaluate thrombophilia in pregnant women in the western part of Romania and to establish anthropometric characteristics, socioeconomic features, and genetic and risk factors. Material and Methods: 178 pregnant women were divided into three study groups, according to the type of thrombophilia, aiming to carry out the genetic profile and the acquired one. Anthropometric measures and biological tests were performed. Results: The mixed type of thrombophilia predominates. The particularities of pregnant women diagnosed with thrombophilia are higher age, living in an urban environment, with normal BMI, approximately 36 weeks of gestational period, and having at least one miscarriage. Regarding the most frequent thrombophilic genetic markers, we obtained the MTFHR gene mutation C677T and A1298C, followed by the PAI-1 4G/5G gene mutation. Smoking represents an aggravating factor in the evolution of this pathology, manifested through the increase of D-dimers and the decrease in antithrombin values, simultaneously with the increase in therapeutic need. Conclusions: The predominance of MTHFR and PAI-1 4G/5G gene polymorphism is a particularity of pregnant women with thrombophilia from the western part of Romania. Smoking is confirmed as an important risk factor in spontaneous abortion.

Keywords: miscarriage; pregnant women; thrombophilia.

MeSH terms

  • Abortion, Spontaneous*
  • Female
  • Humans
  • Infant
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics
  • Mutation
  • Plasminogen Activator Inhibitor 1
  • Pregnancy
  • Pregnant Women
  • Romania / epidemiology
  • Thrombophilia* / genetics

Substances

  • Plasminogen Activator Inhibitor 1
  • Methylenetetrahydrofolate Reductase (NADPH2)

Grants and funding

This research received no external funding.